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Transglutaminase-IIHyaluronic acid (HA), an essential component of the extracellular matrix, is an efﬁcient space ﬁller that
maintains hydration, serves as a substrate for assembly of proteoglycans and is involved in wound healing.
Although numerous pieces of evidence demonstrate beneﬁcial effects in promoting wound healing in
diabetes, a systemic approach has never been tested. We used an incisional wound healing model in
genetically diabetic mice to test the effects of systemic injection of HA. Diabetic (n=56) and normoglycemic
(n=56) mice were subjected to incision and randomized (8 groups of 7 animals each) to receive HA at
different doses, 7.5, 15 and 30 mg/kg/i.p., or vehicle (0.9% NaCl solution) for 12 days. At the end of the
experiment animals were sacriﬁced and skin wounds were excised for histological, biochemical and
molecular analysis. Histology revealed that themost effective dose to improve wound repair and angiogenesis
in diabetic mice was 30 mg/kg. Furthermore HA injection (30 mg/kg) improved the altered healing pattern in
diabetic animals, increased skin remodeling proteins TGF-β and transglutaminase-II and restored the altered
expression of cyclin B1/Cdc2 complex. Evaluation of skin from diabetic animals injected with HA revealed also
an increase in HA content, suggesting that systemic injection may be able to restore the reduced intracellular
HA pool of diabetic mice. Finally HA markedly improved skin mechanical properties. These promising results,
if conﬁrmed in a clinical setting, may improve the care and management of diabetic patients.and Experimental Medicine,
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Diabetic patients have impaired wound healing associated with
increased morbidity and mortality [1,2]. The majority of non-healing
wounds often leads to amputation, thus increasing the direct costs of
their care, rehabilitation, and lost productivity [3]. Clinical and
experimental evidence suggests that diabetic ulcers and other types
of chronic wounds do not follow an orderly and reliable progression of
[1].
Hyaluronic acid (HA) consists of a basic unit of two sugars,
glucuronic acid and N-acetylglucosamine, polymerised into large
macromolecules of over 30,000 repeating units. It is therefore one ofthe largest components of the extracellular matrix and its structure,
highly conserved in evolution, appears identical in rodents and
humans [4]. The molecule is readily soluble in water, producing a gel
and has no allergenic properties, representing an excellent molecule
for clinical applications. HA is formed at the cell surface of ﬁbroblasts
by extrusion into the extracellular matrix in close association with a
dedicated receptor, CD44. Fibroblasts also elaborate hyaluronidase,
the degradation enzyme, and are able to internalize both HA and,
importantly, its breakdown products [5]. Enzymatic degradation
cleaves the HAmacromolecule into smaller polymers, each comprised
of variable lengths of dimeric chains; many of which appear to
modulate wound healing even if studies have indicated that most of
the effects attributed to the molecule are applicable to only few
products. Collagen deposition by ﬁbroblasts is one of the key factors in
reconstituting a supporting matrix at sites of scar formation and it is
the nature of this deposition that largely determines scar quality.
There is evidence that extracellular matrix (ECM) remodeling
following HA application is enhanced and collagen deposition more
Fig. 1. A–D: Haematoxylin–eosin staining at day 12, original magniﬁcation ×10. Rectangle represents the area at higher magniﬁcation (×40) in the lower left corner. A: NDB+vehicle,
shows almost complete re-epithelialization, presence of granulation tissue and inﬂammatory inﬁltrate (see rectangle in the corner). B: NDB+HA7.5 mg/kg, shows advanced healingwith
initial retraction of the granulation tissue, less inﬂammatory inﬁltrate and presence of hair follicles (see rectangle in the corner). C: NDB+HA 15mg/kg, shows complete healing process
with retraction of the granulation tissue, more mature hair follicles and presence of vessels in the site of incision (see rectangle in the corner). D: NDB+HA 30mg/kg, shows no further
improvement in the healing process compared to NDB+HA 15mg/kg. E–H: Masson's tricrhome staining at day 12, original magniﬁcation ×10. Rectangle represents the area at higher
magniﬁcation (×40) in the lower left corner. Bluecolor identiﬁescollagen tissue, red color identiﬁeskeratinandmuscleﬁbers. E:NDB+vehicle, showspresenceof fewandpoorlyarranged
collagen bundles at the incision site (see rectangle in the corner). F: NDB+HA 7.5 mg/kg, showsmore and better arranged collagen ﬁbers at the incision site (see rectangle in the corner).
G:NDB+HA15mg/kg, shows completely restored andmature collagen tissue at the incision site (see rectangle in the corner). H: NDB+HA30mg/kg, shows no improvement in collagen
tissue (see rectangle in the corner).
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expected to increase tissue HA fragments) causes enhanced scarring
[9], whilst persistently raised levels of HA decrease ﬁbroblast
contraction [10]. Furthermore, HA ﬁbroblast production may be
affected by a number of growth factors [11] and HA degradation
products are pro-angiogenic, this effect being limited to fragments of
between 4 and 25 disaccharides in length [12].
The mechanism underlying HA degradation is not completely
understood, but according to the current model, it involves the
concerted action of the somatic hyaluronidases (Hyal-2 and Hyal-1)
with CD44 [13]. Very recently it was also shown that Hyal-1 and -2
mRNAs are up-regulated by exogenous lactate in normal ﬁbroblasts
[14]. After an injury, during the course of wound repair, the level of
oxygen availability decreaseswhereas lactate production increases. This
in turn leads to increased HA turnover and appearance of HA with
smaller molecular weight; furthermore it helps to drive adequate
wound healing. If the regulation of HA catabolismby lactate is impaired,
as it has been shown in ﬁbroblasts from diabetic patients with ulcers
[15], tissue injury may promote accumulation of highmolecular weight
HA and intensiﬁcation of reduced ﬁbroblast proliferation. This effect
may induce transformation of acutewounds into chronic ulcers. Thus, itis possible that both increased accumulation of high molecular weight
HA and the elevated level of CD44 expression may be considered as
additional factors enhancing susceptibility to chronic ulceration in
diabetes.
In addition, HA binding to its cell surface receptor RHAMM is
critical for the progression of cells through the cell cycle. The phases of
cell cycle are controlled by different types of cyclins in a timely and
orderly manner. Cyclins, cyclins-dependent kinases (cdks) and
negative regulators such as cyclin-dependent kinase inhibitors work
together to regulate cell cycle progression [16].
The genetically diabetic mouse represents an useful animal model
for skin healing studies; in fact wound healing in these animals is
markedly delayed when compared with non diabetic littermates.
Healing impairment is characterized by delayed cellular inﬁltration,
impaired granulation tissue formation, reduced angiogenesis, and
decreased collagen synthesis and organization [17–19].
Our group already tested several approaches to improve wound
healing by using an incisional wound model in genetically diabetic
mice [20–24]. In the present study we investigated whether a
systemic injection of HAmight also exert beneﬁcial effect on impaired
cell cycle and tissue remodeling in diabetic wound healing.
Fig. 2. A–D: Haematoxylin–eosin staining at day 12, original magniﬁcation ×10. Rectangle represents the area at higher magniﬁcation (×40) in the lower left corner. A: DB+vehicle,
shows incomplete re-epithelialization, presence of immature granulation tissue and inﬂammatory inﬁltrate (see rectangle in the corner). B: DB+HA 7.5 mg/kg, shows still
incomplete healing with reduced inﬂammatory inﬁltrate and immature granulation tissue (see rectangle in the corner). C: DB+HA 15 mg/kg, shows partially complete healing
process with initial retraction of the granulation tissue (see rectangle in the corner). D: NDB+HA 30 mg/kg, shows further improvement in the healing process, retraction of the
granulation tissue (see rectangle in the corner) and presence of hair follicles (see arrows). E–H: Masson's tricrhome staining at day 12, original magniﬁcation ×10. Rectangle
represents the area at higher magniﬁcation (×40) in the lower left corner. Blue color identiﬁes collagen tissue, red color identiﬁes keratin and muscle ﬁbers. E: DB+vehicle, shows
presence of very few collagen bundles at the incision site (see rectangle in the corner). F: DB+HA 7.5 mg/kg, shows few collagen ﬁbers at the incision site (see rectangle in the
corner). G: DB+HA 15 mg/kg, shows immature collagen tissue at the incision site (see rectangle in the corner). H: DB+HA 30 mg/kg, shows better organized collagen tissue (see
rectangle in the corner).
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2.1. Animals and experimental protocol
All animal procedures were as humane as possible and complied
with the declaration of Helsinki and with the Guide for the Care and
Use of Laboratory Animals.
Genetically diabetic female C57BL/KsJ-m+/+Leptdb mice (DB) and
their normal littermates (NDB) were obtained from Jackson Laboratory
(Bar Harbor, USA). Animals were 10 weeks old at the start of the
experiments. Diabetic mice were obese, weighing 30–35 g, while non-
diabetic littermates weighed 22–25 g. During the experiments the
animals were housed one per cage, maintained under controlled
environmental conditions (12 hour light/dark cycle, temperature
approximately 23 °C) and provided with standard laboratory food and
water ad libitum.
The animals (n=56) were divided into 8 groups of 7 animals each.
After general anesthesia with sodium pentobarbital (80 mg/kg/i.p.),
hair on the back was shaved and skin washed with povidone–iodine
solution and wiped with sterile water.
Two full-thickness longitudinal incisions (4 cm) were made on the
dorsum of the mice and the wound edges were closed with 4–0 silksurgical suture placed at 1-cm intervals. Normoglycemic and diabetic
mice received either high molecular weight HA (4000 kDa; Sigma-
Aldrich, Italy) at different doses (7, 15 and 30 mg/kg/i.p. daily) or its
vehicle (100 μl/i.p. of a 0.9% NaCl solution) for 12 days. The animals
were sacriﬁced after 12 days and the wounds removed by using a
scalpel to cut the shape of an ellipse around the lesion.2.2. Histologic examination
Skin specimens were ﬁxed in 10% neutral buffered formalin; after
ﬁxation, perpendicular sections of the anterior-posterior axis of the
woundwere embedded inparafﬁn. Fivemicrometer thick sectionswere
mounted on glass slides, de-waxed, rehydrated to distilled water and
stained with haematoxylin and eosin or Masson's trichrome according
to routine procedures for light microscopy. As part of the histological
evaluation, all slides were examined by a pathologist without
knowledge of the previous treatment, by means of an eye-piece grid
under the microscope from ×20 to ×100 magniﬁcation. The following
parameters were evaluated: re-epithelialization, dermal matrix depo-
sition and regeneration, granulation tissue formation and remodeling.
The histological parameters adopted in this study were evaluated
Fig. 3. CD31 immunostaining at day 12, original magniﬁcation ×40. Arrows indicate positive staining in small vessels in dermal tissue. A: NDB+vehicle. B: NDB+HA 7.5 mg/kg. C: NDB+HA
15mg/kg.D:NDB+HA30mg/kg. E:DB+vehicle. F:DB+HA7.5 mg/kg.G:DB+HA15mg/kg.H:DB+HA30mg/kg. I: Thebargraph showsmicrovasculardensityquantiﬁcationcarriedoutby
a trained pathologist blinded to treatment, as better speciﬁed in the methods. §pb0.005 vs. NDB+vehicle; *pb0.05 vs. NDB+vehicle; #pb0.05 vs. DB+vehicle; ##pb0.01 vs. DB+vehicle.
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mental models [25].
2.3. Immunohistochemistry
Parafﬁnembedded tissueswere sectioned (5 μ) andantigen retrieval
was performed using citrate buffer from BioGenex (San Ramon, CA,
USA). Tissues were treated with primary antibody against CD31 (Santa
Cruz, USA). Secondary antibody was provided in a kit by Innovex
(Richmond, CA, USA) and the location of the reaction was visualized
with 3,3′diaminobenzidine tetrahydrochloride (Sigma, Milano, Italy).
To assessmicrovessel density (MVD) three to six areas with the highest
staining per section were selected and the number of blood vessels
having a visible lumen was counted (×40 magniﬁcation) by two
pathologists blinded to the samples.
2.4. Tissue hyaluronan sample preparation and HA quantiﬁcation
At the end of the experiment skin from the wound site was
immediately removed and frozen in liquid nitrogen for HA determi-
nation.Weighed amounts of frozen tissue (50 mg)were homogenized
in 1.0 ml of 150 mM Tris–HCl, pH 8.3; 150 mM sodium chloride;
150 mM calcium chloride; 5 mM deferoxamine and 40 IU of protease
K using an Ultra-Turrax homogenizer. The sample was digested
overnight at 55 °C and the homogenates clariﬁed by centrifugation at
4 °C (18,000g for 5 min). Supernatants were collected and placed in a
boiling bath for 20 min to inactivate any proteases.The assay was carried out using a speciﬁc enzyme-linked binding
protein assay test kit (cat no. 029-001, Corgenix, Cambridgeshire, UK).
In brief, the assay uses microwells coated with a highly speciﬁc
hyaluronic acid binding protein (HABP) from bovine cartilage to
capture HA, and an enzyme-conjugated version of HABP to detect and
measure HA. The concentration of HA in each sample was determined
by interpolation from a standard curve ranging from 0 to 800 ng/ml.2.5. Western blot analysis
Skin samples were homogenized in lysis buffer as previously
described 22–24 and after protein determination samples were
denatured in reducing buffer (62 mM Tris pH 6.8, 10% glycerol, 2% SDS,
5% β-mercaptoethanol, 0.003% bromophenol blue) and separated by
electrophoresis on an SDS (12%) polyacrylamide gel. The separated
proteins were transferred on to a nitrocellulose membrane using the
transfer buffer (39 mM glycine, 48 mM Tris, pH 8.3, 20% methanol) at
200 mA for 1 h. The membranes were stained with Ponceau's (0.005% in
1%acetic acid) toconﬁrmequal amountsofproteinandwereblockedwith
5% non fat dry milk in TBS-0.1% Tween for 1 h at room temperature,
washed three times for 10 min each in TBS-0.1% Tween, and incubated
with a primary antibody for TGF-β1, transglutaminase-II, cyclin B1, Cdc2
or p27 (Cell Signaling, Beverly, MA) in TBS-0.1% Tween overnight at 4 °C.
After being washed three times for 10 min each in TBS-0.1% Tween, the
membranes were incubated with a secondary peroxidase-conjugated
antibody (Pierce, Rockford, IL) for 1 hat roomtemperature. Afterwashing,
the membranes were analyzed by the enhanced chemiluminescence's
Fig. 4. A: Hyaluronan skin content following 12 days of systemic administration.
§pb0.005 vs. NDB+vehicle; *pb0.05 vs. NDB+vehicle; #pb0.05 vs. DB+vehicle;
##pb0.01 vs. DB+vehicle. B: RepresentativeWestern blot of TGF-β expression in skin
samples. §pb0.005 vs. NDB+vehicle; *pb0.05 vs. NDB+vehicle; #pb0.05 vs. DB+
vehicle; ##pb0.01 vs. DB+vehicle. C: RepresentativeWestern blot of transglutaminase-II
expression in skin samples. §pb0.005 vs. NDB+vehicle; *pb0.05 vs. NDB+vehicle;
#pb0.05 vs. DB+vehicle; ##pb0.01 vs. DB+vehicle.
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Chalfont, UK). The TGF-β, TG-II, cyclin B1, Cdc2 and p27 protein signals
were quantiﬁed by scanning densitometry using a bio-image analysis
system (Bio-Proﬁl Celbio, Milan, Italy). Equal loading of protein was
assessed on stripped blots by immunodetection of β-actin with a rabbitmonoclonal antibody (Cell Signaling) and a secondary peroxidase-
conjugated antibody (Pierce). All antibodies are puriﬁed by protein A
and peptide afﬁnity chromatography.
2.5.1. Breaking strength
The maximum load (breaking strength) tolerated by wounds was
measured blindly on coded samples using a calibrated tensometer
(Sans, Milan, Italy) as described previously [24]. The ends of the skin
strip were pulled at a constant speed (20 cm min-1), and breaking
strength was expressed as the mean maximum level of tensile
strength in Newton (N) before separation of wounds.
2.6. Statistical analysis
All data are expressed as the mean plus or minus the standard
deviation (mean±SD). Comparisons between different treatments
were analyzed by one-way ANOVA followed by Tukey's multiple
comparison test. In all cases, a probability error of less than 0.05 was
selected as the criterion for statistical signiﬁcance. Graphs were
drawn using GraphPad Prism (version 4.0 for Windows).
3. Results
3.1. Effects of systemic HA on skin healing and angiogenesis
Both vehicle and HA (at the doses of 7.5 and 15 mg/kg) treated NDB
mice showed at day 12 a complete skin repair (Fig. 1A, B and C) with a
well formed granulation and collagen tissue (Fig. 1E, F and G). The
30 mg/kg dose of HAwas associatedwith dermal scar formation in NDB
mice (Fig. 1D and H). Diabetic wounds from animals administered with
vehicle showed at day 12 incomplete re-epithelialization, with a very
low organized granulation tissue (Fig. 2A and E). Increasing doses of HA
(7.5 and 15 mg/kg) improved the healing process in DB mice (Fig. 2B
and C), ameliorating the formation andmaturation of granulation tissue
and collagen bundles (Fig. 2F and G). Complete re-epithelialization and
well formed granulation tissue rich in ﬁbroblasts and collagen were
observed in diabetic wounds of mice treated with the 30 mg/kg dose of
HA (Fig. 2D and H).
To conﬁrm the angiogenic response, CD31 was investigated by
immunostaining. The semi-quantitative assessment of microvascular
density showed overlapping values in NDB mice treated with either
vehicle (Fig. 3A and I) or HA (at 7.5, 15 and 30 mg/kg; Fig. 3B, C, D and I).
By contrast low occurrence of newly formed vessels was observed in
samples obtained from DB animals receiving vehicle (Fig. 3E and I)
when compared with NDB animals. The administration of increasing
doses of HA resulted in a marked enhancement in CD31 staining,
especially at the dose of 30 mg/kg (Fig. 3F, G and H), and with a higher
concentration of newly formed vessels (Fig. 3I).
3.2. Skin content of hyaluronan after systemic administration
Intact skinmeanhyaluronan level was 68.7±5.3 ng/ml in NDBmice
and 43.8±4.5 ng/ml in DBmice, thus suggesting a marked impairment
in hyaluronan content during diabetes. At day 12, hyaluronan levels in
wounds from vehicle-treated NDBmicewere higher (36.2±4.2 ng/ml)
than in vehicle-treated DB mice (17.3±2.7 ng/ml, Fig. 4A). Systemic
administration of HA increased hyaluronan tissue concentration reach-
ing a maximum effect in NDB mice at the dose of 15 mg/kg and in DB
mice at the dose of 30 mg/kg, respectively (Fig. 4A).
3.3. Effects of systemic HA on molecular markers of tissue remodeling
The healing process stimulated TGF-β1 expression in NDB mice
administered with vehicle; this expression was not augmented in
vehicle-treated DBmice (Fig. 4B). HA administration, especially at the
dose of 15 mg/kg, markedly enhanced TGF-β1 expression in NDBmice
Fig. 5. A:RepresentativeWesternblot of cyclin B1expression in skin samples. §pb0.005 vs.NDB+vehicle; *pb0.05 vs. NDB+vehicle; #pb0.05 vs. DB+vehicle; ##pb0.01 vs. DB+vehicle.
B: Representative Western blot of Cdc2 expression in skin samples. §pb0.005 vs. NDB+vehicle; *pb0.05 vs. NDB+vehicle; #pb0.05 vs. DB+vehicle; ##pb0.01 vs. DB+vehicle.
C: RepresentativeWestern blot of p27 expression in skin samples. §pb0.005 vs. NDB+vehicle; #pb0.05 vs. DB+vehicle; ##pb0.01 vs. DB+vehicle. D: Breaking strength of skin samples
following 12 days of systemic administration. §pb0.005 vs. NDB+vehicle; #pb0.05 vs. DB+vehicle; ##pb0.01 vs. DB+vehicle.
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doses of HA showed a signiﬁcant enhancement in TGF-β1 expression,
being the 30 mg/kg dose the most effective one (Fig. 4B). DB mice
treated with vehicle had a lower expression of TG-2 than vehicle-
treated NDB (Fig. 4C). Increasing doses of HA augmented TG-2
expression both in NDB and DB mice; the maximum effect was
observed with the 15 mg/kg dose in NDB and with the 30 mg/kg dose
in DB mice, respectively (Fig. 4C).
3.4. Effects of systemic HA on cell cycle regulators
The cell cycle positive regulators cyclin B1 and its kinase Cdc2,
both speciﬁcally activated during the mitotic phase of the cell cycle,
were evaluated at day 12 post-wounding. NDB animals showed a
robust expression of the two positive regulators; cyclin B1 and Cdc2
were signiﬁcantly up-regulated by HA, being the 15 mg/kg the most
effective dose (Fig. 5A and B). DB animals treated with vehicle had a
lower expression of cyclin B1 (Fig. 5A) and Cdc2 (Fig. 5B) than NDB.
Cyclin B1 and Cdc2 expression was signiﬁcantly increased by HA and
the 30 mg/kg dose produced the maximum effect (Fig. 5A and B).
The cell cycle negative regulator p27 was signiﬁcantly higher at day
12 in DB mice than in NDB, thus suggesting an altered regeneration
process during diabetes (Fig. 5C). Systemic increasing doses of HA (with
a maximum effect observed at 30 mg/kg) succeeded in reducing p27expression in DB animals (Fig. 5C). By contrast HA did not modify the
negative regulator in NDB animals (Fig. 5C).
3.4. Effects of systemic HA on tensile strength of diabetic wounds
Wound breaking strength for each group at day 12 is shown in
Fig. 5D. Wound breaking strength of DB mice was signiﬁcantly lower
than that of NDB animals (pb0.001). HA administration did not further
increase the tensile strengthof thewounds inNDB. Bycontrast, breaking
strength of incisional diabetic wounds was improved by HA treatment
being the 30 mg/kg the most effective dose.
4. Discussion
HA is a major extracellular glycosaminoglycan and is found in most
types of extracellular matrices where it provides primarily a structural
role. The highest HA concentrations are found in typical connective
tissues such as umbilical cord, synovial ﬂuid of joints and the vitreous
body of the eye [26–28]. In marked contrast with all other glycosami-
noglycans (GAGs) HA is not synthesized in the Golgi apparatus, but on
the cytoplasmic surface of the plasma membrane [29]. HA is generally
produced in themesenchymal connective tissue of the body. In animals
HA is formed at the cell surface of ﬁbroblasts by extrusion into the
extracellular matrix in close association with a dedicated receptor,
758 M. Galeano et al. / Biochimica et Biophysica Acta 1812 (2011) 752–759CD44. As well as manufacturing the macromolecule, ﬁbroblasts also
elaborate hyaluronidase [30], the enzyme responsible for its degrada-
tion, and are able to internalize both the original molecule and its
breakdown products [31]. HA production increases during tissue
remodeling and has been already associated with the wound repair
process [32–35]. After tissue injury, HA fragments of lower molecular
mass accumulate, as a result of excessive digestion by hyaluranidase.
GenerationofHA fragments under conditions of tissue injurymay signal
to the host that normal homeostasis has been profoundly disturbed.
Despite their simpleprimary structureHA fragments havewide-ranging
functions inwound healing that are size-speciﬁc [36]. It has been shown
that in human chronic dermal wounds and in intact and wounded skin
of diabetic rats the amount of extracellular matrix components, in
particular HA, is drastically decreased as a result of a reduced rate of
their biosynthesis, increased degradation or a combination of both
phenomena [37,38]. Accordingly, HA content was very low and the
healing process was markedly delayed (in terms of re-epithelialization,
collagen tissue formation and angiogenesis) in our diabetic vehicle-
treatedmice. The systemic administration of HA resulted in a signiﬁcant
improvement in scar formation, collagen synthesis and deposition and
formation of new vessels at the wound site. Furthermore, the Masson's
trichrome stain showed a stimulating action of HA on ﬁbroblasts with
augmented granulation tissue formation, as also conﬁrmed by the
enhanced expression of TGF-β1 and TG-II; this latter has been identiﬁed
as a “natural glue” in the intercellular matrix that plays a key role in all
restorative processes occurring during wound healing. TGF-β1 can
present contradictory effects on skin, but it is well known that this
mediator, released by cells that are localized at sites of tissue repair, such
as platelets, activated macrophages and possibly ﬁbroblasts, exerts
beneﬁcial effects in each phase of wound healing [39,40]. TGF-β1 is
necessary in the inﬂammatory phase for proper chemoattraction of
monocytes; in the proliferative phase, it stimulates extracellular matrix
production and affects angiogenesis and epithelialization, and, more-
over, induces myoﬁbroblast contraction and formation in skin wounds.
Recently, TGF-β1 increased the rate of healing and the breaking strength
of the repaired tissue in aged animals; it also enhanced angiogenesis and
consequent blood ﬂow to dermal wounds in these animals, by
stimulating, at least in part, local release of other growth factors [41].
HA fragments are believed to stimulate cell cycle progression; this
activity seems to be initiated through its binding to both the cell
surface receptor CD44 and the receptor for HA-mediated motility
(RHAMM), resulting in signal transduction activation and ultimately
mitogenesis [42,43]. The mechanism for the HA induced promotion of
cells through the cell cycle may be identiﬁed in the HA–RHAMM
signaling that stimulates Cdc2/cyclin B1 complex kinase activity [43].
Previous data from our laboratory showed that diabetic animals have
an impaired cell cyclemachinery thatmay explain the delayed healing
process [44]. Here we show an increased expression of the speciﬁc
cyclin B1/Cdc2 kinase complex together with a concomitant reduction
in the negative regulator p27 following 12 days of systemic HA
administration. This led us to hypothesize that HA beneﬁcial effects in
the disturbed skin repair process of diabetes may be mainly ascribed
to its ability to restore the impaired cell cycle machinery.
Diabetic animals had lower basal content of HA thannormoglycemic
mice. Thismight explainwhythemosteffectivedoseofHAwasdifferent
between the two strains of mice The highest dose of HA produced the
best results in diabetics, improving signiﬁcantly the wound healing
process and augmenting skin mechanical properties. On the contrary
administration of the highest dose of HA caused dermal scar formation
(ﬁbrosis) in normoglycemic mice. The explanation for this discrepancy
may stem in the normalHA turnover of non diabetic animals. The size of
HA, in fact, inﬂuences its biological activity; small HA oligosaccharides
stimulate angiogenesis and ﬁbroblast proliferation, whereas high levels
of macromolecular HA inhibit angiogenesis and promote ﬁbrosis.
Therefore it is tempting to speculate that the highest dose of HA is not
broken down in normoglycemic animals because the balance betweenformation and degradation of the ECM is in “equilibrium”; this would
cause a lack ofHAdegradation anda consequent excessiveoccurrence of
macromolecular HA that would trigger ﬁbrosis. To date this is the ﬁrst
report showing that systemic administration of HA in diabetic animals
induces an improvement in the healing process together with a
stimulationof the cell cyclemachinery. In additionwepreviously reported
that systemic high-molecular weight HA injection may also reduce
diabetes-induced renal injury [45]. These ﬁndings, taken together, are of
particular importance in a clinical setting; in fact, they suggest that
systemic administration of HA may counteract nephropathy and ulcers,
two of the most severe complication of diabetes.
5. Conclusion
Diabetic ulcers and nephropathy are main causes of morbidity and
mortality in diabetic patients. Systemic HA might be a potential
therapeutic strategy to manage these two diabetic complications that
share, as a common pathogenesis, alterations in the extracellular
matrix turnover.
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